CytoDyn color logo - no R.png
CytoDyn’s Leronlimab Featured on OneNews in Philippines on May 9
May 07, 2021 06:00 ET | CytoDyn Inc.
Drs. Pourhassan, Recknor, Seethamraju and Nicolas will appear in a one-hour segment beginning at 5:00 pm PT / 8:00 pm ET, Sunday, May 9 VANCOUVER, Washington, May 07, 2021 (GLOBE NEWSWIRE) --...
CytoDyn color logo - no R.png
CytoDyn Reaches Agreement with Albert Einstein Israelite Hospital in Brazil to Conduct Two COVID-19 Trials - a Small Trial in Critically Ill and a Large Trial in Severe Populations
May 05, 2021 03:35 ET | CytoDyn Inc.
Interim analysis for critically ill population will be conducted when enrollment reaches about 120 patients or 40% of the approximate 300 patients VANCOUVER, Washington, May 05, 2021 (GLOBE...
CytoDyn color logo - no R.png
CytoDyn to Hold Webcast on May 5 to Provide Update on Multiple Initiatives
May 03, 2021 09:05 ET | CytoDyn Inc.
VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...
CytoDyn color logo - no R.png
Data from 10 Patients with Stage Four Cancer Treated with Leronlimab for Nearly One Year Will Serve as Basis for Pre-Breakthrough Therapy Designation Meeting with FDA
May 03, 2021 09:02 ET | CytoDyn Inc.
VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a...
CytoDyn color logo - no R.png
CytoDyn HIV Indication Update: Leronlimab HIV Extension Arm Nearing 7 Years with Continued Excellent Safety Results
May 03, 2021 09:00 ET | CytoDyn Inc.
Following the successful conclusion of three clinical trials, approximately 120 patients continue treatment with leronlimab in extension arms VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) --...
CytoDyn color logo - no R.png
CytoDyn’s Chief Medical Officer Dr. Scott Kelly to Present at Triple Negative Breast Cancer Drug Development Digital Summit 2021 on April 28
April 27, 2021 16:01 ET | CytoDyn Inc.
VANCOUVER, Washington, April 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140),...
CytoDyn color logo - no R.png
CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants
April 22, 2021 23:52 ET | CytoDyn Inc.
Company Achieves Total Financing in April of $57 Million VANCOUVER, Washington, April 22, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage...
CytoDyn color logo - no R.png
CytoDyn Submits First and Most Crucial Section (CMC) of Interim Order Application to Health Canada for COVID-19 Under Rolling Review
April 19, 2021 06:05 ET | CytoDyn Inc.
Clinical trial in U.S. for critically ill COVID-19 patients expected to initiate soon CytoDyn in discussions with Brazil to initiate two COVID-19 trials, one for severe and one for critically ill...
CytoDyn color logo - no R.png
Former President of the Philippines, Joseph Estrada, Among the Many COVID-19 Patients Receiving Leronlimab Under CSP in the Philippines
April 19, 2021 06:00 ET | CytoDyn Inc.
CytoDyn is following all patients treated with leronlimab under CSP and will provide additional information when available and authorized for release VANCOUVER, Washington, April 19, 2021 (GLOBE...
CytoDyn color logo - no R.png
CytoDyn Executes Exclusive Supply and Distribution Agreement with Chiral Pharma Corporation to Provide Up to 200,000 vials of Leronlimab to Philippines
April 15, 2021 09:26 ET | CytoDyn Inc.
Under Compassionate Special Permit (CSP) in Philippines, CytoDyn is well positioned to generate significant revenues VANCOUVER, Washington., April 15, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:...